ATE440888T1 - Verfahren zur herstellung von glatiramer - Google Patents

Verfahren zur herstellung von glatiramer

Info

Publication number
ATE440888T1
ATE440888T1 AT05824006T AT05824006T ATE440888T1 AT E440888 T1 ATE440888 T1 AT E440888T1 AT 05824006 T AT05824006 T AT 05824006T AT 05824006 T AT05824006 T AT 05824006T AT E440888 T1 ATE440888 T1 AT E440888T1
Authority
AT
Austria
Prior art keywords
glatiramer
producing
producing glatiramer
Prior art date
Application number
AT05824006T
Other languages
English (en)
Inventor
Anup Ray
Hiren Patel
Johannes Ludescher
Mariappan Anbazhagan
Mahendra Patel
Ingolf Macher
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Application granted granted Critical
Publication of ATE440888T1 publication Critical patent/ATE440888T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05824006T 2004-10-29 2005-10-27 Verfahren zur herstellung von glatiramer ATE440888T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62334604P 2004-10-29 2004-10-29
US65137205P 2005-02-09 2005-02-09
US65153505P 2005-02-09 2005-02-09
US72390105P 2005-10-05 2005-10-05
PCT/US2005/039003 WO2006050122A1 (en) 2004-10-29 2005-10-27 Processes for preparing glatiramer

Publications (1)

Publication Number Publication Date
ATE440888T1 true ATE440888T1 (de) 2009-09-15

Family

ID=36046637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05824006T ATE440888T1 (de) 2004-10-29 2005-10-27 Verfahren zur herstellung von glatiramer

Country Status (14)

Country Link
US (5) US20060154862A1 (de)
EP (1) EP1807467B1 (de)
JP (1) JP5297653B2 (de)
CN (1) CN101044188B (de)
AR (1) AR052321A1 (de)
AT (1) ATE440888T1 (de)
AU (1) AU2005302500B2 (de)
CA (1) CA2583589C (de)
DE (1) DE602005016292D1 (de)
ES (1) ES2331015T3 (de)
IL (2) IL182581A (de)
SI (1) SI1807467T1 (de)
TW (1) TWI307349B (de)
WO (1) WO2006050122A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60237170D1 (de) 2001-12-04 2010-09-09 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
ES2331015T3 (es) * 2004-10-29 2009-12-18 Sandoz Ag Proceso para la preparacion de un glatiramero.
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
WO2008006026A1 (en) * 2006-07-05 2008-01-10 Momenta Pharmaceuticals, Inc. Improved process for the preparation of copolymer-1
EP2381254B2 (de) 2007-06-21 2017-07-19 Momenta Pharmaceuticals, Inc. Copolymeranalyse
WO2009017775A2 (en) * 2007-08-02 2009-02-05 Scinopharm Taiwan Ltd. Process for the preparation of a polypeptide
EP2277050B2 (de) 2008-04-16 2022-09-28 Momenta Pharmaceuticals, Inc. Analyse von aminosäurecopolymerzusammensetzungen
KR20110059606A (ko) * 2008-08-07 2011-06-02 시노팜 타이완 리미티드 글라티라머 아세테이트의 합성
WO2010017075A1 (en) 2008-08-07 2010-02-11 Sigma-Aldrich Co. Preparation of low molecular weight polylysine and polyornithine in high yield
US9617313B2 (en) 2008-12-24 2017-04-11 Synthon Bv Process for purifying a polymer mixture
US8859489B2 (en) 2009-04-03 2014-10-14 Momenta Pharmaceuticals, Inc. Water-mediated control of depolymerization step of glatiramer acetate synthesis
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
ATE549013T1 (de) * 2009-07-15 2012-03-15 Teva Pharma Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren
UA103699C2 (ru) 2009-08-20 2013-11-11 Еда Рисёрч Энд Девелопмент Ко., Лтд. Терапия глатирамера ацетатом с низкой частотой
MX2012005749A (es) * 2009-11-17 2012-10-03 Ares Trading Sa Metodos para mejorar el diseño, la biodisponibilidad de composiciones de polimero de secuencia dirigida, por medio de la deteccion basada en proteinas del suero, de composiciones de polimero de secuencia dirigida.
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EP2563804A4 (de) * 2010-04-27 2014-09-17 Reddys Lab Ltd Dr Herstellung von polypeptiden und salzen davon
US9109006B2 (en) * 2010-07-29 2015-08-18 Santhanakrishnan Srinivasan Glatiramer acetate molecular weight markers
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
CA2827275A1 (en) 2011-02-14 2012-09-20 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
WO2012114167A1 (en) * 2011-02-24 2012-08-30 Biocon Limited Processes for the preparation of glatiramer acetate
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
CA2851510A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
EP2773652A1 (de) * 2011-11-03 2014-09-10 Biocon Limited Verfahren zur herstellung von statistischen polypeptiden und verwendung von zirkularem dichroismus als anleitungswerkzeug zur herstellung von glatirameracetat
US20140045740A1 (en) * 2012-08-13 2014-02-13 Momenta Pharmaceuticals, Inc. Analysis of glatiramer acetate
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
DK3433430T3 (da) 2016-03-23 2022-09-05 Alm Holding Co Batch-asfaltblandeanlæg
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US12370233B2 (en) 2016-08-31 2025-07-29 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate
WO2018178973A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
CN107082796B (zh) * 2017-05-02 2020-06-09 江苏大学 一种提纯蛋白酶解物中小分子多肽的方法
GB2579600B (en) 2018-12-05 2023-07-05 Byotrol Plc Anti-viral composition
US12058799B2 (en) 2019-07-01 2024-08-06 A.L.M. Holding Company Microwave suppression tunnel and related features

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2657972A (en) * 1952-09-06 1953-11-03 Robert B Woodward Copolymer of l-leucine and dl-phenylalanine
US3704282A (en) * 1971-04-09 1972-11-28 Sidney Spector Catecholamine antigens and antibodies specific therefor
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
HU174500B (hu) * 1976-05-05 1980-01-28 Richter Gedeon Vegyeszet Sposob poluchenija slozhnogo oktapeptidamid-sul'fatnogo ehfira kholecistokhinin-pankreozimina
JPS6053535A (ja) * 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
AU596986B2 (en) 1985-06-18 1990-05-24 Emory University Biologically-active copolymers
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
CA2009996A1 (en) 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
GB9411292D0 (en) 1994-06-06 1994-07-27 Teva Pharma Pharmaceuticals compositions
WO1997026245A1 (en) * 1996-01-16 1997-07-24 Lumigen, Inc. Compounds, compositions and methods for generating chemiluminescence with phosphatase enzymes
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6514935B1 (en) * 1997-03-14 2003-02-04 President And Fellows Of Harvard Methods of treating hypertension
US6632541B2 (en) * 1998-02-10 2003-10-14 Sumitomo Chemical Company, Limited Olefin-based copolymer composition
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
EP1107974B1 (de) * 1998-08-27 2006-08-02 Teva Pharmaceutical Industries Ltd. Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
EP1128839A4 (de) 1998-11-12 2002-10-09 Yeda Res & Dev Pharmazeutische zusammensetzungen enthaltend kopolymere synthetischer peptide und methoden zur vorbeugung und behandlung von gvhd und hvgd
JP2000256395A (ja) * 1999-01-07 2000-09-19 Takeda Chem Ind Ltd ポリオール類、その製造法および用途
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
US6531130B1 (en) * 1999-07-06 2003-03-11 The Board Of Trustees Of The Leland Stanford University Treatment of demyelinating autoimmune disease with ordered peptides
US6963008B2 (en) * 1999-07-19 2005-11-08 Teva Pharmaceutical Industries Ltd. Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6995237B1 (en) * 1999-10-27 2006-02-07 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
PT1248643E (pt) * 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
AU2002240057A1 (en) * 2001-01-24 2002-08-06 President And Fellows Of Harvard College Therapeutic peptides for demyelinating conditions
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
AU2003283152A1 (en) * 2002-11-13 2004-06-03 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
CA2411786C (en) * 2002-11-13 2009-01-27 Brantford Chemicals Inc. A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
US6936539B2 (en) * 2003-09-24 2005-08-30 Micron Technology, Inc. Antireflective coating for use during the manufacture of a semiconductor device
MX2007002760A (es) * 2004-09-09 2007-05-18 Teva Pharma Procedimiento para la preparacion de mezclas de polipeptidos y utilizando acido bromhidrico purificado.
ES2331015T3 (es) * 2004-10-29 2009-12-18 Sandoz Ag Proceso para la preparacion de un glatiramero.
US8420605B2 (en) * 2005-09-07 2013-04-16 The University Of Strathclyde Hydrogel compositions

Also Published As

Publication number Publication date
US8536305B2 (en) 2013-09-17
US20100234272A1 (en) 2010-09-16
AU2005302500A1 (en) 2006-05-11
IL233618A0 (en) 2014-08-31
CA2583589C (en) 2012-04-24
US8729229B2 (en) 2014-05-20
TW200634051A (en) 2006-10-01
US20100174048A1 (en) 2010-07-08
AR052321A1 (es) 2007-03-14
IL182581A0 (en) 2007-07-24
US20080021200A1 (en) 2008-01-24
JP2008518930A (ja) 2008-06-05
US20100234566A1 (en) 2010-09-16
SI1807467T1 (sl) 2009-12-31
DE602005016292D1 (de) 2009-10-08
CA2583589A1 (en) 2006-05-11
IL233618A (en) 2016-05-31
AU2005302500B2 (en) 2008-11-27
CN101044188A (zh) 2007-09-26
JP5297653B2 (ja) 2013-09-25
US20060154862A1 (en) 2006-07-13
IL182581A (en) 2015-09-24
ES2331015T3 (es) 2009-12-18
TWI307349B (en) 2009-03-11
WO2006050122A1 (en) 2006-05-11
EP1807467B1 (de) 2009-08-26
EP1807467A1 (de) 2007-07-18
CN101044188B (zh) 2010-08-04

Similar Documents

Publication Publication Date Title
ATE440888T1 (de) Verfahren zur herstellung von glatiramer
ATE408609T1 (de) Verfahren zur herstellung von n-phenylpyrazol-1- carboxamiden
DE602005019848D1 (de) Verfahren zur herstellung von tad- getrocknetem ti
ATE408604T1 (de) Verfahren zur herstellung von 1-alkyl-3- phenyluracilen
ATE399761T1 (de) Verfahren zur herstellung von dinitrilen
ATE516816T1 (de) Verfahren zur herstellung von impfstoffen
ATE479409T1 (de) Verfahren zur herstellung von saugkernen
ATE455105T1 (de) Verfahren zur herstellung von difluormethylpyrazolylcarboxylaten
ATE476411T1 (de) Verfahren zur herstellung von 3-pentennitril
DE602006015090D1 (de) Verfahren zur herstellung von gezielt durchlässigen laminaten
ATE480531T1 (de) Verfahren zur herstellung von benzopyran-2- olderivaten
ATE489015T1 (de) Verfahren zur herstellung von verschlüssen
ATE457969T1 (de) Verfahren zur herstellung von aloe-emodin
ATE308524T1 (de) Verfahren zur herstellung von aripiprazole
ATE399157T1 (de) Verfahren zur herstellung von telmisartan
DE602004022134D1 (de) Verfahren zur herstellung von dinitrilen
ATE553103T1 (de) Verfahren zur herstellung von (s)-pantoprazol
DE502005001997D1 (de) Verfahren zur herstellung von silanisierten kohlenstoff-nanoröhren
ATE453619T1 (de) Verfahren zur herstellung von hydroperoxiden
DE502004004318D1 (de) Verfahren zur herstellung von metall-matrix-verbundwerkstoffen
DE50303611D1 (de) Verfahren zur herstellung von polyisobuten
ATE444303T1 (de) Verfahren zur herstellung von ferrisuccinylcasein
ATE406372T1 (de) Verfahren zur herstellung von 3-o-geschützten morphinonen und 3-o-geschützten morphinondienolcarboxylaten
ATE466843T1 (de) Verfahren zur herstellung von n-piperidino-1,5- diphenylpyrazol-3-carboxamid-derivaten
ATE549314T1 (de) Verfahren zur herstellung von 4-aminochinazolinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1807467

Country of ref document: EP